Nucleic Acid Therapeutic Delivery – ZRG1 BBBT (81)
Begins for upcoming October/November 2022 application deadlines, with first review dates in February/March 2023. It was created as part of CSR’s ENQUIRE process which functions to align study sections with advances in science.
The Nucleic Acid Therapeutic Delivery (ZRG1 BBBT (81)) study section reviews applications focused on fundamental aspects of nucleic acid delivery, including intracellular delivery, delivery vehicle development, targeting strategies, and overcoming biological barriers. Applications are typically focused on bioengineering principles and may not be hypothesis driven.
Review Dates
Topics
- Delivery of therapeutics based on nucleic acid delivery, including siRNA, mRNA, DNA, oligonucleotide therapies.
- Studies developing mRNA Vaccines
- Delivery vehicles including plasmids, viruses, liposomes, micelles, vesicles, nanoparticles, biomaterials, polycationic polymers and lipids, and cells.
- Targeting strategies via aptamers.
- Delivery strategies including light and physical methods (optical caging, Electroporation, Ultrasound)
- Study of the biological barriers to nucleic acid delivery (e.g., membrane, tissue, cellular, trafficking, physical).
- Studies of the interactions of delivery vehicles, devices, and/or payloads with the immune system and host tissue related to nucleic acid therapeutic delivery.
Shared Interests and Overlaps
There are shared interests in drug discovery with Drug and Biologic Therapeutic Delivery (DBTD). Applications that focus on fundamental aspects of nucleic acid delivery, including intracellular delivery, delivery vehicle development, targeting strategies, and overcoming biological barriers are reviewed in BBBT (81). Applications that emphasize fundamental aspects of therapeutic delivery of cargoes of synthetic and biologic nature except nucleic acids are reviewed in DBTD.
There are shared interests in nano-therapeutics with Innovations in Nanosystems and Nanotechnology (INN). Applications that focus on biological delivery and targeting issues involving the use of nanocarriers for nucleic acids are reviewed in BBBT (81). Applications that focus on unique features of multifunctional nanoparticles, nanobiomaterials, DNA scaffolds, and delivery and targeting platforms as well as their chemical properties and synthesis are reviewed in INN.
There are shared interests in therapeutic delivery with Advancing Therapeutics A (ATA). Applications that focus on vehicle development and targeting strategies for nucleic acid, small molecules and biologics are reviewed in BBBT (81). Applications that focus on vehicle development and targeting strategies for preclinical cancer therapeutic studies are reviewed in ATA.
There are shared interests in nucleic acid-based therapeutics with Advancing Therapeutics B (ATB). Applications that emphasize fundamental design, delivery, and targeting of nucleic acid therapies are reviewed in BBBT (81). Applications that emphasize efficacy, safety, or toxicity in animal models or pilot clinical trials are reviewed in ATB.
There are shared interests in therapeutic systems and nuclei acid delivery with the Drug and Biologic Disposition and Toxicity (DBDT). Applications that examine the fundamental aspects of nucleic acid delivery, are reviewed in BBBT (81). Mechanistic and preclinical applications that focus on the disposition and safety and toxicity of delivery agents are reviewed in DBDT.
There are shared interests in mRNA vaccine development with Vaccines Against Infectious Diseases (VID). Applications that emphasize vaccine testing, efficacy, and immune responses may be reviewed in VID. Applications that emphasize novel methods for vaccine delivery, with a focus on bioengineering principles, may be reviewed in BBBT (81).
